1. Home
  2. ASTH vs NAMS Comparison

ASTH vs NAMS Comparison

Compare ASTH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASTH
  • NAMS
  • Stock Information
  • Founded
  • ASTH 1994
  • NAMS 2019
  • Country
  • ASTH United States
  • NAMS Netherlands
  • Employees
  • ASTH N/A
  • NAMS N/A
  • Industry
  • ASTH Professional Services
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASTH Consumer Discretionary
  • NAMS Health Care
  • Exchange
  • ASTH Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • ASTH 2.0B
  • NAMS 1.7B
  • IPO Year
  • ASTH N/A
  • NAMS N/A
  • Fundamental
  • Price
  • ASTH $33.70
  • NAMS $25.50
  • Analyst Decision
  • ASTH Strong Buy
  • NAMS Strong Buy
  • Analyst Count
  • ASTH 6
  • NAMS 6
  • Target Price
  • ASTH $68.20
  • NAMS $36.20
  • AVG Volume (30 Days)
  • ASTH 315.5K
  • NAMS 1.4M
  • Earning Date
  • ASTH 11-07-2024
  • NAMS 02-06-2025
  • Dividend Yield
  • ASTH N/A
  • NAMS N/A
  • EPS Growth
  • ASTH 34.92
  • NAMS N/A
  • EPS
  • ASTH 1.30
  • NAMS N/A
  • Revenue
  • ASTH $1,722,367,000.00
  • NAMS $33,594,000.00
  • Revenue This Year
  • ASTH $46.11
  • NAMS $129.49
  • Revenue Next Year
  • ASTH $32.82
  • NAMS N/A
  • P/E Ratio
  • ASTH $25.89
  • NAMS N/A
  • Revenue Growth
  • ASTH 29.71
  • NAMS 78.77
  • 52 Week Low
  • ASTH $33.46
  • NAMS $10.50
  • 52 Week High
  • ASTH $63.20
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • ASTH 18.80
  • NAMS 62.30
  • Support Level
  • ASTH $34.32
  • NAMS $24.40
  • Resistance Level
  • ASTH $38.11
  • NAMS $26.95
  • Average True Range (ATR)
  • ASTH 1.52
  • NAMS 1.66
  • MACD
  • ASTH -0.27
  • NAMS 0.41
  • Stochastic Oscillator
  • ASTH 2.11
  • NAMS 81.51

About ASTH Astrana Health Inc. Common Stock

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: